ISIS

Isis Pharmaceuticals, Inc. Press Releases

$63.65
*  
4.16
6.99%
Get ISIS Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading ISIS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
12/7/2014 2:05:00 PM - PR Newswire
▲20.64 % Price Change since this news event. The Volume Ratio is 2.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals'' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
12/5/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
12/5/2014 7:00:00 AM - PR Newswire
▲20.82 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
12/3/2014 5:05:00 PM - PR Newswire
▲18.42 % Price Change since this news event. The Volume Ratio is 1.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
11/25/2014 7:00:00 AM - PR Newswire


ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
11/20/2014 4:47:00 PM - PR Newswire


ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
11/20/2014 4:47:00 PM - PR Newswire


Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
11/18/2014 3:45:00 PM - Business Wire


Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
11/18/2014 7:00:00 AM - PR Newswire


Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award
11/17/2014 12:04:00 PM - PR Newswire


Isis Pharmaceuticals to Present at Upcoming Investor Conferences
11/14/2014 7:00:00 AM - PR Newswire
▲24.56 % Price Change since this news event. The Volume Ratio is 0.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
11/13/2014 3:01:00 AM - PR Newswire
▲25.30 % Price Change since this news event. The Volume Ratio is 0.72.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
11/12/2014 7:00:00 AM - PR Newswire
▲23.93 % Price Change since this news event. The Volume Ratio is 1.38.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
11/10/2014 4:03:00 PM - PR Newswire
▲36.15 % Price Change since this news event. The Volume Ratio is 5.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
11/7/2014 8:30:00 AM - PR Newswire
▲39.06 % Price Change since this news event. The Volume Ratio is 1.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
11/6/2014 7:00:00 AM - PR Newswire
▲44.66 % Price Change since this news event. The Volume Ratio is 0.94.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
11/5/2014 7:00:00 AM - PR Newswire
▲39.58 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters'' Option to Purchase Additional Shares
11/3/2014 4:05:00 PM - PR Newswire


Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
11/3/2014 7:00:00 AM - PR Newswire
▲36.85 % Price Change since this news event. The Volume Ratio is 0.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
10/31/2014 7:00:00 AM - PR Newswire
▲38.37 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
10/30/2014 7:00:00 AM - PR Newswire
▲42.08 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Pricing of Public Offering of Common Stock
10/28/2014 8:10:00 PM - PR Newswire


Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
10/10/2014 4:30:00 AM - PR Newswire
▲71.10 % Price Change since this news event. The Volume Ratio is 2.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
10/9/2014 7:00:00 AM - PR Newswire
▲62.79 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
10/2/2014 7:00:00 AM - PR Newswire